GlassScriptPhysician profile
Micah Relic
NPI 1548680010
$20,405.52
in general payments reported to CMS, 2019-2025
27 companies · $632 in 2025
The $632 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $113 · 2021: $214 · 2022: $151 · 2023: $19K · 2024: $263 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $17K · Food and Beverage: $1,940 · Travel and Lodging: $1,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $16,500.00 |
| Food and Beverage | $1,939.72 |
| Travel and Lodging | $1,329.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $18,044.55 | 2023 | Davinci Xi, Da Vinci Surgical System |
| Abbvie INC. | $400.28 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $247.14 | 2023-2025 | |
| Organon LLC | $219.90 | 2021-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $204.00 | 2023-2025 | Fluent Fluid Management System, Myosure Tissue Removal Device, Omni Hysteroscope |
| Sumitomo Pharma America, INC. | $194.21 | 2023-2025 | Myfembree |
| Coopersurgical, INC. | $173.63 | 2020-2025 | Paragard T 380a |
| Astellas Pharma US INC | $154.63 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $92.43 | 2019 | |
| Therapeuticsmd, INC. | $74.68 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.87 | 2023-2025 | |
| Dexcom, INC. | $65.90 | 2025 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $56.11 | 2023-2024 | Ultomiris |
| Innovation Technologies INC | $50.02 | 2023-2025 | Irrisept |
| Millicent US INC | $48.29 | 2023-2025 | Femring, Intrarosa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $46.36 | 2021-2024 | |
| Exeltis, USA INC. | $40.63 | 2023-2025 | Slynd |
| Minerva Surgical, INC | $35.92 | 2023 | |
| Exact Sciences Corporation | $35.32 | 2023-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $29.62 | 2022-2023 | Truclear |
| Myovant Sciences INC. | $18.88 | 2021 | |
| Becton, Dickinson and Company | $18.80 | 2023 | Bd Onclarity |
| Kowa Pharmaceuticals America, INC. | $18.14 | 2023 | Seglentis |
| Amag Pharmaceuticals, INC. | $17.80 | 2019 | |
| Novo Nordisk INC | $16.81 | 2023 | Wegovy |
| Mylan Pharmaceuticals INC. | $16.51 | 2021 | |
| Currax Pharmaceuticals LLC | $16.09 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Micah Relic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.